NYSE:ZTSPharmaceuticals
A Look At Zoetis (ZTS) Valuation After Analyst Downgrades And Softer Guidance
Multiple analyst downgrades following Zoetis (ZTS) flat revenue quarter and slightly softer full year guidance have pushed the stock under closer scrutiny, as concerns build around an expected near term innovation air pocket.
See our latest analysis for Zoetis.
That caution has shown up clearly in the trading data, with Zoetis’ 90 day share price return of -15.92% and 1 year total shareholder return of -25.36% pointing to fading momentum as investors reassess near term risks around the...